Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin Effect on Serum YKL40 in Acne Vulgaris
NCT05218486Phase 4Unknown
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of isotretinoin in acne vulgaris (2 arms). Primary endpoint: Serum YKL40 at 3 months. Status: unknown.
02
Drugs
isotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05218486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218486.